Dr. Childs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5410 Netherland Avenue
Riverdale, NY 10471Phone+1 917-214-7887Fax+1 862-404-4303
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1982 - 1985
Rutgers Robert Wood Johnson Medical SchoolClass of 1982, MD
Certifications & Licensure
NY State Medical License 1983 - 2026
FL State Medical License 1993 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, Kristopher Wentzel, Funan Huang
Cancer Research Communications. 2025-03-01 - Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large...Georg Lenz, Eliza Hawkes, Gregor Verhoef, Corinne Haioun, Soon Thye Lim
Leukemia. 2024-02-01 - 15 citationsSafety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian ca...Alessandro D Santin, Ignace Vergote, Antonio González-Martín, Kathleen Moore, Ana Oaknin
International Journal of Gynecological Cancer. 2023-04-03
Lectures
- Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
